Advances in immunotherapy for MMR proficient colorectal cancer.
View/ Open
Date
2022-12-01ICR Author
Author
Lote, H
Starling, N
Pihlak, R
Gerlinger, M
Type
Journal Article
Metadata
Show full item recordAbstract
Survival in mismatch-repair proficient (MMRp) metastatic colorectal cancer (mCRC) remains poor and chemotherapy is the mainstay of treatment. Immunotherapy has demonstrated durable responses and a favourable side-effect profile in various cancer types and multiple clinical trials have been conducted in MMRp mCRC. In this review we summarise emerging trial data which demonstrate promising immunotherapy combinations in MMRp mCRC. We outline barriers to success, evaluate emerging biomarkers and discuss potential strategies to increase the effectiveness of immunotherapy in MMRp mCRC.
Collections
Subject
Humans
DNA Mismatch Repair
Colorectal Neoplasms
Immunotherapy
Research team
Transl Oncogenomics
Language
eng
Date accepted
2022-10-26
License start date
2022-12-01
Citation
Cancer Treatment Reviews, 2022, 111 pp. 102480 -
Publisher
ELSEVIER SCI LTD